Thus, targeting MDM2-p53 interaction is a particularly attractive therapeutic strategy for p53 reactivation in tumors.1054,1055 Numerous small-molecule MDM2 inhibitors have been discovered so far, and nine of them, including RG7112, idasanutlin, AMG-232, SAR40583, APG-115, NVP-CGM097, siremadlin, and MK-8242, and milademetan, have undergone or been undergoing clinical trials for the treatment of cancers.1028. The gene discussed is TP53; the disease is cancer.